Atossa Therapeutics Inc. [NASDAQ: ATOS] slipped around -1.12 points on Friday, while shares priced at $4.50 at the close of the session, down -19.93%. The company report on July 15, 2021 that Physician-Scientist Steven Quay and an International Team of Scientists and Investigators Provide Science-Based Analysis of the Origin of COVID-19 to the US Congress.
An international team of scientists and data analysts, led by Physician-Scientist Steven Quay, MD, PhD, has published a paper entitled, “Science Not Speculation Should Inform the Investigation of the Origin of COVID-19,” in which they conclude: “Until new evidence is found, an investigation of the pathway for the origin of COVID-19 should proceed with the assumption that a laboratory-acquired infection or research-related accident is at least as likely, if not more likely, than a natural zoonotic transmission.”.
The paper was submitted to the Subcommittee on Investigations and Oversight hearing, Principles for Outbreak Investigation: COVID-19 and Future Infectious Diseases,” held on July 14, 2021.
Atossa Therapeutics Inc. stock is now 373.68% up from its year-to-date (YTD) trading value. ATOS Stock saw the intraday high of $5.82 and lowest of $4.32 per share. The company’s 52-week high price is 9.80, which means current price is +414.29% above from all time high which was touched on 06/25/21.
Compared to the average trading volume of 20.19M shares, ATOS reached a trading volume of 44240760 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Atossa Therapeutics Inc. [ATOS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATOS shares is $7.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATOS stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Atossa Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2018.
The Average True Range (ATR) for Atossa Therapeutics Inc. is set at 1.06 The Price to Book ratio for the last quarter was 3.00, with the Price to Cash per share for the same quarter was set at 1.14.
How has ATOS stock performed recently?
Atossa Therapeutics Inc. [ATOS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.41. With this latest performance, ATOS shares dropped by -3.23% in over the last four-week period, additionally plugging by 260.00% over the last 6 months – not to mention a rise of 12.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATOS stock in for the last two-week period is set at 41.15, with the RSI for the last a single of trading hit 34.34, and the three-weeks RSI is set at 45.47 for Atossa Therapeutics Inc. [ATOS]. The present Moving Average for the last 50 days of trading for this stock 4.74, while it was recorded at 5.68 for the last single week of trading, and 2.67 for the last 200 days.
Atossa Therapeutics Inc. [ATOS]: Deeper insight into the fundamentals
Return on Total Capital for ATOS is now -72.33, given the latest momentum, and Return on Invested Capital for the company is -88.40. Return on Equity for this stock declined to -88.42, with Return on Assets sitting at -62.18. When it comes to the capital structure of this company, Atossa Therapeutics Inc. [ATOS] has a Total Debt to Total Equity ratio set at 0.07. Additionally, ATOS Total Debt to Total Capital is recorded at 0.07, with Total Debt to Total Assets ending up at 0.04.
Reflecting on the efficiency of the workforce at the company, Atossa Therapeutics Inc. [ATOS] managed to generate an average of -$2,228,494 per employee.Atossa Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 102.30 and a Current Ratio set at 102.30.
Insider trade positions for Atossa Therapeutics Inc. [ATOS]
There are presently around $49 million, or 12.20% of ATOS stock, in the hands of institutional investors. The top three institutional holders of ATOS stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 3,304,140, which is approximately 570.483% of the company’s market cap and around 0.04% of the total institutional ownership; VANGUARD GROUP INC, holding 3,180,565 shares of the stock with an approximate value of $14.31 million in ATOS stocks shares; and BLACKROCK INC., currently with $6.89 million in ATOS stock with ownership of nearly 228940.658% of the company’s market capitalization.
Positions in Atossa Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 48 institutional holders increased their position in Atossa Therapeutics Inc. [NASDAQ:ATOS] by around 9,307,636 shares. Additionally, 7 investors decreased positions by around 73,138 shares, while 0 investors held positions by with 1,421,952 shares. The mentioned changes placed institutional holdings at 10,802,726 shares, according to the latest SEC report filing. ATOS stock had 36 new institutional investments in for a total of 1,412,059 shares, while 4 institutional investors sold positions of 1,900 shares during the same period.